Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses (2019 - 2022)

C4 Therapeutics has reported Other Accumulated Expenses over the past 4 years, most recently at $309000.0 for Q1 2022.

  • For Q1 2022, Other Accumulated Expenses fell 65.16% year-over-year to $309000.0; the TTM value through Mar 2022 reached $309000.0, down 65.16%, while the annual FY2021 figure was $413000.0, 11.94% down from the prior year.
  • Other Accumulated Expenses for Q1 2022 was $309000.0 at C4 Therapeutics, down from $413000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $887000.0 in Q1 2021 and troughed at $164000.0 in Q3 2020.
  • A 4-year average of $370750.0 and a median of $294500.0 in 2019 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 67.5% in 2020 and later plummeted 65.16% in 2022.
  • Year by year, Other Accumulated Expenses stood at $280000.0 in 2019, then soared by 67.5% to $469000.0 in 2020, then dropped by 11.94% to $413000.0 in 2021, then decreased by 25.18% to $309000.0 in 2022.
  • Business Quant data shows Other Accumulated Expenses for CCCC at $309000.0 in Q1 2022, $413000.0 in Q4 2021, and $201000.0 in Q3 2021.